Contents

Foreword XIII
List of Contributors XV

1 Analytical Validation within the Pharmaceutical Lifecycle 1
Phil Nethercote and Joachim Ermer
1.1 Development of Process and Analytical Validation Concepts 1
1.2 Alignment between Process and Analytics: Three-Stage Approach 4
1.3 Predefined Objectives: Analytical Target Profile 5
1.4 Analytical Life Cycle 8
References 9

2 Analytical Instrument Qualification 11
Christopher Burgess and R. D. McDowall
2.1 Analytical Instrument and System Qualification 11
2.1.1 Data Quality and Integrity in a GMP Environment 11
2.1.1.1 Criteria for Quality Data 11
2.1.1.2 Regulatory Rationale for Qualified Analytical Instruments 12
2.1.2 USP General Chapter <1058> 12
2.1.2.1 Data Quality Triangle 14
2.1.2.2 Analytical Instrument Qualification Life Cycle: the Four Qs Model 14
2.1.2.3 Risk-Based Classification of Apparatus, Instruments, and Systems 15
2.1.2.4 Roles and Responsibilities for AIQ 17
2.1.2.5 Software Validation for Group B and C Systems 18
2.1.3 Enhancement of <1058> and Harmonization of a Risk-Based Approach to Instruments and Systems with GAMP Laboratory GPG Second Edition 18
2.1.3.1 Increased Granularity of USP <1058> Groups 18
2.1.3.2 Clarification of AIQ Terminology 19
2.1.3.3 A Continuum of Analytical Apparatus, Instruments, and Systems 19
2.1.3.4 Mapping USP <1058> Instrument Groups to GAMP Software Categories 20
2.1.3.5 Enhanced Data Quality Triangle 20
2.1.4 Risk-Based Approaches to Analytical Instrument and System Qualification 20
2.1.4.1 Expanded <1058> Instrument and System Categories 23
2.2 Efficient and Economic HPLC Performance Qualification 25

Hermann Wätzig

2.2.1 Introduction 25
2.2.1.1 The Importance of Analytical Instrument Qualification 25
2.2.1.2 Terms and Definitions 25
2.2.1.3 Continuous Performance Qualification: More by Less 27
2.2.2 Development of the Revised OQ/PQ Parameters List 27
2.2.3 Transfer of Modular Parameters into the Holistic Approach 29
2.2.3.1 Autosampler 29
2.2.3.2 Solvent Delivery System 29
2.2.3.3 Detector 30
2.2.4 OQ/PQ Data in Comparison with SST Data 32
2.2.5 Control Charts 33
2.2.6 General Procedure for Continuous PQ 34
2.2.7 Concluding Remarks 36

Acknowledgment 37
Abbreviations 37
References 38

3 Establishment of Measurement Requirements – Analytical Target Profile and Decision Rules 41

Mary Lee Jane Weitzel

3.1 Introduction 41
3.2 Defining the Fitness for Intended Use 42
3.3 Decision Rules 42
3.4 Overview of Process to Develop Requirements for Procedure Performance 43
3.5 Decision Rules and Compliance 43
3.6 Calculating Target Measurement Uncertainty 45
3.6.1 Coverage Factor, k, and Data Distributions 46
3.7 Types of Decision Rules 47
3.7.1 Decision Rules That Use Guard Bands 48
3.8 Target Measurement Uncertainty in the Analytical Target Profile 49
3.8.1 Cost of Analysis 49
3.9 Bias and Uncertainty in a Procedure 50
3.10 ATP and Key Performance Indicators 51
3.11 Measurement Uncertainty 51
3.11.1 What Uncertainty Is 51
3.11.2 Reporting Measurement Uncertainty 52
3.11.3 How Uncertainty is Estimated  54
3.11.4 Uncertainty Contains All Sources of Random Variability  55
3.12 Example  56
3.13 Conclusion  57
References  58

4 Establishment of Measurement Requirements – Performance-Based Specifications  59
  Todd L. Cecil
4.1 Introduction  59
4.2 Intended Purpose  60
4.3 Identification  60
4.4 Assay  62
  4.4.1 Precision  62
  4.4.2 Accuracy  63
  4.4.3 Precision and Accuracy  64
    4.4.3.1 Relationship between Accuracy and Precision  64
  4.4.4 Specificity  65
    4.4.4.1 Chromatographic Procedures  65
    4.4.4.2 Non-chromatographic Procedures  66
  4.4.5 Linearity and Range  67
    4.4.5.1 Linearity  67
    4.4.5.2 Range  67
  4.5 Impurities  68
  4.6 Limit Tests  69
    4.6.1 Limit of Detection  69
    4.6.2 Precision  70
    4.6.3 Specificity  70
  4.7 Quantitative Tests  70
    4.7.1 Accuracy  70
    4.7.2 Precision  71
    4.7.3 Specificity and Range  71
  4.8 Summary  71
References  71

5 Method Performance Characteristics  73
  Joachim Ermer
5.1 Introduction  73
5.2 Precision  74
  5.2.1 Distribution of Data  74
    5.2.1.1 The Normal Distribution and its Parameters  74
  5.2.2 Robust Parameter  84
  5.2.2.1 System or Instrument Precision  85
  5.2.2.2 Repeatability  86
5.2.2.3 Intermediate Precision and Reproducibility  86
5.2.3 Calculation of Precisions and Variances  89
5.2.3.1 Analysis of Variances (ANOVA)  90
5.2.3.2 Calculation of Precision from Linear Regression  92
5.2.4 Concentration Dependency of Precision  93
5.2.5 Precision Acceptance Criteria  95
5.2.5.1 Precision of the Reportable Result  95
5.2.5.2 Optimization of the Calibration Format  97
5.2.5.3 Acceptable Precision for Assay  101
5.2.5.4 Acceptable Precision for Impurities and Minor Components  105
5.2.6 Precisions Benchmarks  107
5.2.6.1 Precisions for LC Assay  108
5.2.7 Sources to Obtain and Supplement Precisions  116
5.2.7.1 Precisions from Stability  117
5.2.8 Precision Highlights  119
5.3 Accuracy and Range  119
5.3.1 Drug Substance  122
5.3.1.1 Significance Tests  122
5.3.1.2 Equivalence Tests  124
5.3.1.3 Direct Comparison  125
5.3.1.4 Comparison Examples  125
5.3.2 Drug Product  126
5.3.2.1 Percentage Recovery  127
5.3.2.2 Recovery Function  128
5.3.2.3 Standard Addition  128
5.3.2.4 Accuracy of Drug Product by Comparison  129
5.3.3 Impurities/Degradants  129
5.3.3.1 Recovery of Spiked Impurities  129
5.3.3.2 Accuracy of the Integration Mode  130
5.3.3.3 Response Factors  131
5.3.4 Acceptance Criteria (ATP Requirements)  132
5.3.4.1 Can this Theoretically Obtained Relationship be Supported by Experimental Results?  135
5.3.5 Joint Evaluation of Accuracy and Precision  136
5.3.6 Accuracy Highlights  137
5.4 Specificity  137
5.4.1 Demonstration of Specificity by Accuracy  140
5.4.2 Chromatographic Resolution  140
5.4.3 Peak Purity (Co-elution)  141
5.4.3.1 Rechromatography  141
5.4.3.2 Diode Array Detection  142
5.4.3.3 LC-MS  143
5.4.4 Specificity Highlights  145
5.5 Linearity  145
5.5.1 Unweighted Linear Regression  147
5.5.1.1 Graphical Evaluation of Linearity 151
5.5.1.2 Numerical Regression Parameters 153
5.5.1.3 Statistical Linearity Tests 155
5.5.1.4 Evaluation of the Intercept (Absence of Systematic Errors) 158
5.5.2 Weighted Linear Regression 160
5.5.3 Appropriate Calibration Models 162
5.5.4 Nonlinear and Other Regression Techniques 162
5.5.5 Linearity Highlights 163
5.6 Detection and Quantitation Limit 164
5.6.1 Requirements in Pharmaceutical Impurity Determination 164
5.6.1.1 Intermediate Quantitation Limit 166
5.6.1.2 General Quantitation Limit 166
5.6.2 Approaches Based on the Blank 167
5.6.3 Determination of DL/QL from Linearity 167
5.6.3.1 Standard Deviation of the Response 169
5.6.3.2 95% Prediction Interval of the Regression Line 171
5.6.3.3 Approach Based on German Standard DIN 32645 172
5.6.3.4 From the Relative Uncertainty 173
5.6.4 Precision Based Approaches 174
5.6.5 Comparison of the Various Approaches 175
5.6.6 Quantitation Limit Highlights 176
5.7 Glossary 177
Acknowledgments 182
References 182

6 Method Design and Understanding 191
6.1 Method Selection, Development, and Optimization 191
*Melissa Hanna-Brown, Roman Szucs, and Brent Harrington*
6.1.1 Introduction 191
6.1.2 Method Selection 192
6.1.3 Method Development 194
6.1.4 Method Optimization 205
Acknowledgments 217
6.2 Analytical Quality by Design and Robustness Investigations 217
*Rosario LoBrutto*
6.2.1 Introduction 217
6.2.2 Method Validation Requirements 220
6.2.3 Robustness 221
6.2.4 Analytical Quality by Design 223
6.2.5 Design of Experiments (DOE) 225
6.2.6 FMEA (Failure Mode Effect Analysis) 227
6.2.7 Illustrative Case Study 231
6.2.8 Illustrative Example for Statistical Analysis 234
6.2.9 Control Strategy 239
6.2.10 Conclusions 240
6.3 Case Study: Robustness Investigations 241
Gerd Kleinschmidt

6.3.1 Introduction 241
6.3.2 General Considerations in the Context of Robustness Testing 242
6.3.2.1 Basic and Intrinsic Parameters 243
6.3.3 Examples of Computer-Assisted Robustness Studies 245
6.3.3.1 Robustness Testing Based on Chromatography Modeling Software 246
6.3.3.2 Robustness Testing Based on Experimental Design 258

6.4 System Suitability Tests 287
Joachim Ermer

6.4.1 Chromatographic System Suitability Parameters 288
6.4.1.1 Signal-to-Noise Ratio 289
6.4.1.2 Test for Required Detectability 291
6.4.1.3 Injection Precision 292
6.4.1.4 System Precision for Impurities? 293
6.4.2 Non-chromatographic System Suitability Parameters 293
6.4.3 Design of System Suitability Tests 294

7 Method Performance Qualification 303
7.1 Introduction 303
Joachim Ermer

7.1.1 Example of a Precision Study 305
7.2 Case Study: Qualification of an HPLC Method for Identity, Assay, and Degradation Products 308
Gerd Kleinschmidt

7.2.1 Introduction 308
7.2.2 Experimental 310
7.2.3 Qualification Summary 310
7.2.4 Qualification Methodology 314
7.2.4.1 Specificity 314
7.2.4.2 Linearity 314
7.2.4.3 Accuracy 318
7.2.4.4 Precision 320
7.2.4.5 Quantitation Limit 321
7.2.4.6 Range 323
7.2.5 Conclusion 324
7.3 Design and Qualification of a Delivered Dose Uniformity Procedure for a Pressurized Metered Dose Inhaler 324
Andy Rignall

7.3.1 Introduction 324
7.3.1.1 Analytical Procedures for Complex Dosage Forms 324
7.3.1.2 Human and Environmental Factors Associated with Complex Laboratory Procedures 325
7.3.1.3 Delivered Dose Uniformity Testing for Inhalation Products 325
7.3.2 Designing a Delivered Dose Uniformity Procedure that will Meet an ATP 326
7.3.2.1 Risk Assessment and Classification 327
7.3.2.2 Noise Factors Associated with Dose Collection 331
7.3.2.3 Dose Recovery and Sample Preparation 333
7.3.2.4 Automated Delivered Dose Uniformity Procedure 333
7.3.2.5 Results Calculation and Reporting 334
7.3.3 Performance Characteristics of the Delivered Dose Uniformity Procedure 334
7.3.4 Qualification of the Delivered Dose Uniformity Procedure 335
7.3.5 Summary of the Analytical Control Strategy for a Delivered Dose Uniformity Procedure 336
Acknowledgment 337

7.4 Implementation of Compendial/Pharmacopeia Test Procedures 337
Pauline McGregor
7.4.1 Background of Pharmacopeia Procedures 337
7.4.2 How Pharmacopeia Methods are Generated and Published 338
7.4.3 Challenges with Compendial Procedures and the Need to Verify 338
7.4.4 Using Pharmacopeia Procedures in a Laboratory for the First Time 339
7.4.5 Current Approach to Verification of Pharmacopeia Procedures 339
7.4.6 Integration of the Current Verification Process and the Lifecycle Approach 340
7.4.7 Implementation of a Pharmacopeia Procedure Using the Lifecycle Approach 341
7.4.7.1 Gather Knowledge 341
7.4.7.2 Finalizing the ATP 346
7.4.8 Performance Qualification 347
7.4.9 Conclusion 348
7.5 Transfer of Analytical Procedures 348
Christophe Agut and Joachim Ermer
7.5.1 Transfer Process and Strategy 349
7.5.1.1 Regulatory and International Guidance 349
7.5.1.2 Transfer Process 350
7.5.2 Comparative Testing 355
7.5.2.1 Equivalence-Based Methodology 355
7.5.2.2 Direct Comparison 369
Acknowledgments 372
References 372
8 Continued Method Performance Verification 377
Phil Nethercote and Christopher Burgess
8.1 Introduction 377
8.2 Routine Monitoring 377
  8.2.1 Introduction 377
  8.2.2 Establishing a Control Chart 380
  8.2.3 Examples of Application of Control Charting to Analytical Procedures 382
    8.2.3.1 Example 1 382
    8.2.3.2 Example 2 382
  8.2.4 Periodic Review 383
  8.2.5 Determination of Root Cause Using CuSum Analysis 385
8.3 Investigating and Addressing Aberrant Data 391
  8.3.1 Laboratory Failure Investigation 391
  8.3.2 Classification of Atypical or Aberrant Results 393
  8.3.3 Statistical Outlier Tests for Out-of-Expectation Results 399
  8.3.4 Summary 405
8.4 Continual Improvement 406
  8.4.1 Introduction 406
  8.4.2 Control of Change 406
    8.4.2.1 Risk Assessment of Changes 407
References 409

Index 411